Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 469

1.

Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time.

Pylväläinen J, Talala K, Murtola T, Taari K, Raitanen J, Tammela TL, Auvinen A.

Clin Epidemiol. 2019 Oct 18;11:923-932. doi: 10.2147/CLEP.S218697. eCollection 2019.

2.

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.

Booth N, Rissanen P, Tammela TLJ, Kujala P, Stenman UH, Taari K, Talala K, Auvinen A.

PLoS One. 2019 Nov 5;14(11):e0224479. doi: 10.1371/journal.pone.0224479. eCollection 2019.

3.

Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.

Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K.

Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0.

4.

Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.

Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A; FinnProstate Group.

Eur Urol. 2019 Nov;76(5):586-595. doi: 10.1016/j.eururo.2019.07.001. Epub 2019 Jul 30.

PMID:
31375279
5.

Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland.

Santala EEE, Kotsar A, Veitonmäki T, Tammela TLJ, Murtola TJ.

Scand J Urol. 2019 Jun 28:1-8. doi: 10.1080/21681805.2019.1634147. [Epub ahead of print]

PMID:
31250699
6.

Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.

Kinnunen PTT, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Cancer Causes Control. 2019 Aug;30(8):877-888. doi: 10.1007/s10552-019-01195-x. Epub 2019 Jun 17.

PMID:
31209595
7.

Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?

Carlsson SV, Månsson M, Moss S, Kwiatkowski M, Recker F, Tammela TLJ, Bangma C, Roobol MJ, Auvinen A, Hugosson J.

Eur Urol. 2019 Jun;75(6):1015-1022. doi: 10.1016/j.eururo.2019.03.010. Epub 2019 Mar 28.

PMID:
30928162
8.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators.

Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.

PMID:
30824296
9.

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators.

N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14.

PMID:
30763142
10.

Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort.

Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Scand J Urol. 2018 Oct - Dec;52(5-6):321-327. doi: 10.1080/21681805.2018.1559882. Epub 2019 Jan 30.

PMID:
30698056
11.

Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.

Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):483-490. doi: 10.1038/s41391-019-0129-2. Epub 2019 Jan 29.

PMID:
30696944
12.

Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Sälli SM, Talala K, Taari K, Tammela TLJ, Auvinen A.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):453-460. doi: 10.1038/s41391-018-0123-0. Epub 2019 Jan 24.

PMID:
30679762
13.

Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer.

Lindberg A, Talala K, Kujala P, Stenman UH, Taari K, Kilpeläinen TP, Tammela TL, Auvinen A.

Int J Cancer. 2019 Aug 1;145(3):632-638. doi: 10.1002/ijc.32129. Epub 2019 Feb 4.

PMID:
30653262
14.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2019 Feb;51(2):363. doi: 10.1038/s41588-018-0330-6.

PMID:
30622367
15.

Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men.

Åkerla J, Pesonen JS, Pöyhönen A, Häkkinen J, Koskimäki J, Huhtala H, Tammela TLJ, Auvinen A.

Prostate Cancer Prostatic Dis. 2019 May;22(2):317-323. doi: 10.1038/s41391-018-0108-z. Epub 2018 Nov 8.

PMID:
30410016
16.

Severity and bother of lower urinary tract symptoms among men aged 30-80 years: Tampere Ageing Male Urological Study (TAMUS).

Pöyhönen A, Åkerla J, Häkkinen JT, Koskimäki J, Tammela TLJ, Auvinen A.

Scand J Urol. 2018 Aug;52(4):296-301. doi: 10.1080/21681805.2018.1505944. Epub 2018 Nov 1.

PMID:
30382800
17.

Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.

Li-Sheng Chen S, Ching-Yuan Fann J, Sipeky C, Yang TK, Yueh-Hsia Chiu S, Ming-Fang Yen A, Laitinen V, Tammela TLJ, Stenman UH, Auvinen A, Schleutker J, Chen HH.

J Urol. 2019 Mar;201(3):486-495. doi: 10.1016/j.juro.2018.10.015.

PMID:
30366021
18.

Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy.

Rantaniemi L, Tammela TLJ, Kujala P, Murtola TJ.

Scand J Urol. 2018 Aug;52(4):269-276. doi: 10.1080/21681805.2018.1492967. Epub 2018 Oct 26.

PMID:
30362865
19.

The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).

Pakarainen T, Nevalainen J, Talala K, Taari K, Raitanen J, Kujala P, Stenman UH, Tammela TLJ, Auvinen A.

Clin Cancer Res. 2019 Jan 15;25(2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. Epub 2018 Oct 15.

PMID:
30322875
20.

Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.

Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):66-76. doi: 10.1038/s41391-018-0087-0. Epub 2018 Sep 13.

PMID:
30214034
21.

Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer.

Sipeky C, Gao P, Zhang Q, Wang L, Ettala O, Talala KM, Tammela TLJ, Auvinen A, Wiklund F, Wei GH, Schleutker J.

Clin Cancer Res. 2018 Dec 15;24(24):6265-6276. doi: 10.1158/1078-0432.CCR-18-0444. Epub 2018 Sep 4.

22.

Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus.

Gao P, Xia JH, Sipeky C, Dong XM, Zhang Q, Yang Y, Zhang P, Cruz SP, Zhang K, Zhu J, Lee HM, Suleman S, Giannareas N, Liu S; PRACTICAL Consortium, Tammela TLJ, Auvinen A, Wang X, Huang Q, Wang L, Manninen A, Vaarala MH, Wang L, Schleutker J, Wei GH.

Cell. 2018 Jul 26;174(3):576-589.e18. doi: 10.1016/j.cell.2018.06.003. Epub 2018 Jul 19.

23.

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.

Murtola TJ, Syvälä H, Tolonen T, Helminen M, Riikonen J, Koskimäki J, Pakarainen T, Kaipia A, Isotalo T, Kujala P, Tammela TLJ.

Eur Urol. 2018 Dec;74(6):697-701. doi: 10.1016/j.eururo.2018.06.037. Epub 2018 Jul 18.

PMID:
30031572
24.

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.

Kallio HML, Hieta R, Latonen L, Brofeldt A, Annala M, Kivinummi K, Tammela TL, Nykter M, Isaacs WB, Lilja HG, Bova GS, Visakorpi T.

Br J Cancer. 2018 Aug;119(3):347-356. doi: 10.1038/s41416-018-0172-0. Epub 2018 Jul 10.

25.

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men.

Kaapu KJ, Rantaniemi L, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ.

Sci Rep. 2018 Jul 9;8(1):10308. doi: 10.1038/s41598-018-28541-4.

26.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

27.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. Erratum in: Nat Genet. 2019 Feb;51(2):363.

28.

Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease.

Tolonen TT, Riikonen J, Tammela TLJ, Koivusalo L, Haapasalo H, Kujala P, Kaipia A.

Ann Diagn Pathol. 2018 Aug;35:80-84. doi: 10.1016/j.anndiagpath.2018.06.001. Epub 2018 Jun 5. No abstract available.

PMID:
29886397
29.

Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.

Mäkelä VJ, Kotsar A, Tammela TLJ, Murtola TJ.

J Urol. 2018 Oct;200(4):743-748. doi: 10.1016/j.juro.2018.04.082. Epub 2018 May 3.

PMID:
29730200
30.

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Vihervuori VJ, Lahtela J, Talala K, Taari K, Tammela TL, Auvinen A.

Br J Cancer. 2018 May;118(9):1248-1254. doi: 10.1038/s41416-018-0055-4. Epub 2018 Mar 22.

31.

Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.

Booth N, Rissanen P, Tammela TLJ, Taari K, Talala K, Auvinen A.

Eur J Cancer. 2018 Apr;93:108-118. doi: 10.1016/j.ejca.2018.01.111. Epub 2018 Mar 20.

PMID:
29501976
32.

Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.

Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L; Investigators of the Scandinavian Prostate Cancer Study Number 12.

Eur Urol. 2018 Jun;73(6):870-876. doi: 10.1016/j.eururo.2018.01.012. Epub 2018 Feb 1.

PMID:
29395502
33.

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TL, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Cuk K, Saum KU, Park JY, Sellers TA, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Karow DS, Mills IG, Andreassen OA, Dale AM; PRACTICAL Consortium*.

BMJ. 2018 Jan 10;360:j5757. doi: 10.1136/bmj.j5757.

34.

Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.

FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, Wright JL, Eeles R, Kote-Jarai Z, Govindasami K, Giles GG, Southey MC, Schleutker J, Tammela TL, Sipeky C, Penney KL, Stampfer MJ, Gronberg H, Wiklund F, Stattin P, Hugosson J, Karyadi DM, Ostrander EA, Feng Z, Stanford JL.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):228-237. doi: 10.1038/s41391-017-0029-2. Epub 2018 Jan 3.

35.

Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.

Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):373-378. doi: 10.1038/s41391-017-0031-8. Epub 2017 Dec 22.

PMID:
29273728
36.

The expression of AURKA is androgen regulated in castration-resistant prostate cancer.

Kivinummi K, Urbanucci A, Leinonen K, Tammela TLJ, Annala M, Isaacs WB, Bova GS, Nykter M, Visakorpi T.

Sci Rep. 2017 Dec 21;7(1):17978. doi: 10.1038/s41598-017-18210-3.

37.

Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.

Neupane S, Steyerberg E, Raitanen J, Talala K, Pylväläinen J, Taari K, Tammela TL, Auvinen A.

Int J Urol. 2018 Mar;25(3):270-276. doi: 10.1111/iju.13508. Epub 2017 Dec 10.

38.

A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Assel M, Sjöblom L, Murtola TJ, Talala K, Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela TL, Lilja H.

Eur Urol Focus. 2019 Jul;5(4):561-567. doi: 10.1016/j.euf.2017.11.002. Epub 2017 Nov 11.

PMID:
29137895
39.

Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.

Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS.

Am J Surg Pathol. 2018 Jan;42(1):103-115. doi: 10.1097/PAS.0000000000000961.

PMID:
28984675
40.

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.

Kinnunen PTT, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

BMC Cancer. 2017 Aug 29;17(1):585. doi: 10.1186/s12885-017-3579-8.

41.

Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.

Saarimäki L, Hugosson J, Tammela TL, Carlsson S, Talala K, Auvinen A.

Eur Urol Focus. 2019 Mar;5(2):186-191. doi: 10.1016/j.euf.2017.07.007. Epub 2017 Aug 10.

PMID:
28803925
42.

A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Oksala N, Pettersson K, Tammela TL.

Eur J Epidemiol. 2017 Jun;32(6):521-527. doi: 10.1007/s10654-017-0292-5. Epub 2017 Jul 31.

PMID:
28762124
43.

Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.

Murtola TJ, Vettenranta AM, Talala K, Taari K, Stenman UH, Tammela TLJ, Auvinen A.

Eur Urol Focus. 2018 Dec;4(6):851-857. doi: 10.1016/j.euf.2017.03.005. Epub 2017 Mar 24.

PMID:
28753870
44.

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.

Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K.

Eur Urol Focus. 2018 Jul;4(4):547-553. doi: 10.1016/j.euf.2017.01.015. Epub 2017 Feb 14.

45.

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.

Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela TL, Joensuu H, Aspegren J, Mustonen M.

Eur Urol Focus. 2017 Dec;3(6):606-614. doi: 10.1016/j.euf.2017.01.010. Epub 2017 Feb 27.

46.

Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Peltomaa AI, Talala K, Määttänen L, Taari K, Tammela TLJ, Auvinen A.

Eur Urol Focus. 2017 Apr;3(2-3):212-220. doi: 10.1016/j.euf.2016.05.004. Epub 2016 Jun 2.

PMID:
28753762
47.

Components of metabolic syndrome and prognosis of renal cell cancer.

Eskelinen TJ, Kotsar A, Tammela TLJ, Murtola TJ.

Scand J Urol. 2017 Dec;51(6):435-441. doi: 10.1080/21681805.2017.1352616. Epub 2017 Jul 26.

PMID:
28743221
48.

An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.

Tammela TL, Häggman M, Ladjevardi S, Taari K, Isotalo T, Lennernäs H, Weis J, von Below C, Wassberg C, Lennernäs B, Tolf A, Axén N, Gölander CG, Ahlström H.

J Urol. 2017 Dec;198(6):1333-1339. doi: 10.1016/j.juro.2017.07.072. Epub 2017 Jul 20.

PMID:
28736321
49.

A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).

Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J.

Prostate. 2017 Aug;77(11):1213-1220. doi: 10.1002/pros.23380. Epub 2017 Jun 28.

50.

Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment.

Lehto US, Aromaa A, Tammela TL.

Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12729. Epub 2017 Jun 21.

PMID:
28634991

Supplemental Content

Loading ...
Support Center